CORT vs. AXSM, RARX, GBT, HRMY, TARO, JAZZ, PRGO, SUPN, PCRX, and NKTR
Should you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Axsome Therapeutics (AXSM), Ra Pharmaceuticals (RARX), Global Blood Therapeutics (GBT), Harmony Biosciences (HRMY), Taro Pharmaceutical Industries (TARO), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Nektar Therapeutics (NKTR). These companies are all part of the "medical" sector.
Corcept Therapeutics (NASDAQ:CORT) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.
Corcept Therapeutics currently has a consensus target price of $40.10, suggesting a potential upside of 32.91%. Axsome Therapeutics has a consensus target price of $121.92, suggesting a potential upside of 66.03%. Given Axsome Therapeutics' higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Corcept Therapeutics.
Corcept Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Corcept Therapeutics received 102 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. Likewise, 70.66% of users gave Corcept Therapeutics an outperform vote while only 68.67% of users gave Axsome Therapeutics an outperform vote.
In the previous week, Corcept Therapeutics had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 14 mentions for Corcept Therapeutics and 10 mentions for Axsome Therapeutics. Corcept Therapeutics' average media sentiment score of 0.86 beat Axsome Therapeutics' score of 0.58 indicating that Corcept Therapeutics is being referred to more favorably in the media.
93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Corcept Therapeutics has a net margin of 22.38% compared to Axsome Therapeutics' net margin of -118.07%. Corcept Therapeutics' return on equity of 24.19% beat Axsome Therapeutics' return on equity.
Corcept Therapeutics has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Corcept Therapeutics beats Axsome Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Corcept Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corcept Therapeutics Competitors List
Related Companies and Tools
